A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Abituzumab (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Acronyms STRATUS
- Sponsors EMD Serono
- 07 Feb 2018 Status changed from recruiting to discontinued.
- 06 Feb 2018 This trial has been Discontinued in Spain (end date: 2018-01-17)
- 18 Dec 2017 Planned End Date changed from 17 Dec 2019 to 31 Oct 2023.